At Acetylon Pharmaceuticals, our first responsibility is to patients and their families. This is the passion that unites us and keeps us committed to our mission --- working until there is a cure. We appreciate that patients are individuals, whom we encounter in our everyday lives. Our organization has an open, caring, and compassionate atmosphere that drives our dynamic team to make the world a healthier place to live. In the end, we are people helping people.
All of us at Acetylon are involved in patient-centered research. Acetylon began with the alignment of a new chemical discovery by scientists at Harvard University’s Broad Institute together with the medical insights of our Founding hematologic oncologists at Harvard Medical School and the Dana-Farber Cancer Institute. Together, they postulated potential mechanisms of action for important new drugs to treat multiple myeloma and other diseases.
Supported by investors who care about drug development, Acetylon’s Founders gathered an experienced senior management team that has enjoyed many successes across the spectrum of activities required to bring needed new therapies to market in both the US and Europe.
Our team is working rapidly and productively to advance promising lead compounds through lead optimization, drug candidate selection, preclinical development, and into human clinical trials. In fact, it took us just two years to transition our lead oral HDAC6 inhibitor drug candidate, ricolinostat (ACY-1215), from early stage lead identification to FDA allowance of an Investigational New Drug (IND) application to begin a Phase 1-2 clinical trial to treat multiple myeloma patients.
Everyone involved with Acetylon believes in what the company stands for.
We were founded by those who have worked to transform the scientific understanding and treatment of myeloma.
We have been funded by those whose lives have been touched by disease.
We continue to be validated by other leaders in cancer treatment.
We are led by example.